Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care.
Del Rivero J, Mailman J, Rabow MW, Chan JA, Creed S, Kennecke HF, Pasieka J, Zuar J, Singh S, Fishbein L. Del Rivero J, et al. Among authors: mailman j. Endocr Relat Cancer. 2023 Jun 21;30(7):e220226. doi: 10.1530/ERC-22-0226. Print 2023 Jul 1. Endocr Relat Cancer. 2023. PMID: 37017232 Free PMC article. Review.
The World Association of Radiopharmaceutical and Molecular Therapy position statement on the initial radioiodine therapy for differentiated thyroid carcinoma.
Dizdarevic S, Tulchinsky M, McCready VR, Mihailovic J, Vinjamuri S, Buscombe JR, Lee ST, Frangos S, Sathekge M, Siraj Q, Choudhury P, Bom H, Franceschi M, Ugrinska A, Paez D, Hussain R, Mailman J, Luster M, Virgolini I; WARMTH Thyroid Group. Dizdarevic S, et al. Among authors: mailman j. World J Nucl Med. 2019 Apr-Jun;18(2):123-126. doi: 10.4103/wjnm.WJNM_117_18. World J Nucl Med. 2019. PMID: 31040741 Free PMC article. No abstract available.
NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy.
Hope TA, Bodei L, Chan JA, El-Haddad G, Fidelman N, Kunz PL, Mailman J, Menda Y, Metz DC, Mittra ES, Pryma DA, Reidy-Lagunes DL, Singh S, Strosberg JR. Hope TA, et al. Among authors: mailman j. J Nucl Med. 2020 Feb;61(2):222-227. doi: 10.2967/jnumed.119.240911. J Nucl Med. 2020. PMID: 32015164 Free PMC article. No abstract available.
Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting.
Singh S, Hope TA, Bergsland EB, Bodei L, Bushnell DL, Chan JA, Chasen BR, Chauhan A, Das S, Dasari A, Del Rivero J, El-Haddad G, Goodman KA, Halperin DM, Lewis MA, Lindwasser OW, Myrehaug S, Raj NP, Reidy-Lagunes DL, Soares HP, Strosberg JR, Kohn EC, Kunz PL; NET CTPM participants. Singh S, et al. J Natl Cancer Inst. 2023 Sep 7;115(9):1001-1010. doi: 10.1093/jnci/djad096. J Natl Cancer Inst. 2023. PMID: 37255328 Free PMC article.
Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
Del Rivero J, Perez K, Kennedy EB, Mittra ES, Vijayvergia N, Arshad J, Basu S, Chauhan A, Dasari AN, Bellizzi AM, Gangi A, Grady E, Howe JR, Ivanidze J, Lewis M, Mailman J, Raj N, Soares HP, Soulen MC, White SB, Chan JA, Kunz PL, Singh S, Halfdanarson TR, Strosberg JR, Bergsland EK. Del Rivero J, et al. Among authors: mailman j. J Clin Oncol. 2023 Nov 10;41(32):5049-5067. doi: 10.1200/JCO.23.01529. Epub 2023 Sep 29. J Clin Oncol. 2023. PMID: 37774329
Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET.
Singh S, Ferone D, Capdevila J, Chan JA, de Herder WW, Halperin D, Mailman J, Hellström L, Liedman H, Svedberg A, Tiberg F. Singh S, et al. Among authors: mailman j. Trials. 2024 Jan 16;25(1):58. doi: 10.1186/s13063-023-07834-8. Trials. 2024. PMID: 38229199 Free PMC article. Clinical Trial.
Correction: Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET.
Singh S, Ferone D, Capdevila J, Chan JA, de Herder WW, Halperin D, Mailman J, Hellström L, Liedman H, Svedberg A, Tiberg F. Singh S, et al. Among authors: mailman j. Trials. 2024 May 2;25(1):297. doi: 10.1186/s13063-024-08146-1. Trials. 2024. PMID: 38698434 Free PMC article. No abstract available.
Education Competencies for Integrative Oncology-Results of a Systematic Review and an International and Interprofessional Consensus Procedure.
Witt CM, Balneaves LG, Carlson LE, Cohen M, Deng G, Fouladbakhsh JM, Kinney AY, Mehta A, Mailman J, Pole L, Rogge AA, O'Toole C, Zick SM, Helmer SM. Witt CM, et al. Among authors: mailman j. J Cancer Educ. 2022 Jun;37(3):499-507. doi: 10.1007/s13187-020-01829-8. J Cancer Educ. 2022. PMID: 32783117 Free PMC article.
47 results